Sabiad develops the StaphMark technology, which utilizes a 1D9 antibody tracer for real-time imaging and targeted therapy of Staphylococcus aureus infections. This approach addresses the challenge of hard-to-diagnose infections that form biofilms, enabling precise detection and localized treatment to improve patient outcomes and reduce reliance on broad-spectrum antibiotics.
Funding
Funding not disclosed
Founders
Product
Problem
Surgical site infections caused by Staphylococcus aureus (SA) are increasingly difficult to manage, particularly in orthopedic procedures, often forming biofilms that are hard to diagnose and shield the bacteria from antibiotic treatment. This leads to prolonged hospital stays, increased healthcare costs, and poorer patient outcomes.
Solution
Sabiad develops StaphMark, a theranostic technology that combines real-time imaging with targeted therapy for Staphylococcus aureus infections. StaphMark utilizes a 1D9 antibody tracer to precisely detect SA infections, even those protected by biofilms. This allows for localized treatment, reducing the need for broad-spectrum antibiotics and protecting surrounding healthy tissue. The technology aims to improve infection management by enabling earlier intervention and more effective treatment strategies.
Target Audience
The primary users are infectious disease specialists, orthopedic surgeons, clinicians, and hospital administrators seeking improved diagnostics and targeted treatments for bacterial infections, particularly those caused by Staphylococcus aureus.
Features
- Real-time detection of bacterial infections using the StaphMark solution.
- Targeted treatments that focus on infections while protecting healthy tissues.
- Disruption of biofilms to reduce the chances of infection recurrence.
- Localized therapies to reduce reliance on broad-spectrum antibiotics.
- Utilizes a patented 1D9 antibody tracer for pinpoint precision in targeting SA infections.
- Supports both in vivo and ex vivo applications.